Skip to main content

Table 2 Clinical characteristics of the study subjects with and without good glycemic control during the study period at baseline and at the end of 24 months of treatment

From: Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study

Parameters

GC < 7.0 (n = 72)

GC ≥ 7.0 (n = 24)

Baseline

24 M

p value

Baseline

24 M

p value

Age

70 ± 9

  

67 ± 9

  

Gender (m/f)

49/23

  

13/11

  

BMI

25.3 ± 3.6

25.4 ± 3.8

ns

26.1 ± 4.9

25.8 ± 5.0

ns

SBP (mmHg)

128 ± 13#

130 ± 16

ns

136 ± 16

135 ± 17

ns

DBP (mmHg)

71 ± 10

72 ± 9*

ns

75 ± 13

77 ± 9

ns

HR (beats/min)

68 ± 12

69 ± 13

ns

70 ± 11

70 ± 10

ns

Hemoglobin A1c (%)

6.7 ± 0.4**

6.4 ± 0.3**

p < 0.001

7.5 ± 0.7

7.5 ± 0.7

ns

MDA-LDL (U/L)

106 ± 39

118 ± 34

P = 0.005

111 ± 52

124 ± 42

ns

CRP (ng/mL)

1104 ± 1559

1768 ± 6874

ns

658 ± 745

907 ± 1181

ns

1,5 AG (μg/mL)

17.3 ± 7.2

20.4 ± 8.3

p < 0.001

11.3 ± 7.1

10.4 ± 6.2

ns

  1. GC < 7.0 subjects with good glycemic control, GC > 7.0 subjects with poor glycemic control, 24 M at the end of 24 months of treatment, MDA-LDL serum concentration of malondialdehyde low density-lipoprotein cholesterol concentrations, CRP serum concentration of C-reactive protein, 1,5 AG serum 1,5 anhydroglucitol concentrations, p value comparison between the baseline and after 24 months of treatment, # p = 0.062, * p < 0.050 and ** p < 0.010 vs. subjects without good glycemic control, Other abbreviations are as described in the footnote for Table 1
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840